Siegel R.L. Miller K.D. Jemal A.

Cancer statistics, 2020.

CA. Cancer J. Clin. 2020; 70: 7-30https://doi.org/10.3322/caac.21590Senkomago V. Henley S.J. Thomas C.C. et al.

Human papillomavirus–attributable cancers — United States, 2012–2016.

MMWR. Morb. Mortal. Wkly. Rep. 2019; 68: 724-728https://doi.org/10.15585/mmwr.mm6833a3Gillison M.L. Koch W.M. Capone R.B. et al.

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

J. Natl. Cancer Inst. 2000; 92: 709-720https://doi.org/10.1093/jnci/92.9.709Ang K.K. Harris J. Wheeler R. et al.

Human papillomavirus and survival of patients with oropharyngeal cancer.

N. Engl. J. Med. 2010; 363: 24-35https://doi.org/10.1056/NEJMoa0912217Gillison M.L. Trotti A.M. Harris J. et al.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial.

Lancet. 2019; 393: 40-50https://doi.org/10.1016/S0140-6736(18)32779-XKimple R.J. Smith M.A. Blitzer G.C. et al.

Enhanced radiation sensitivity in HPV-positive head and neck cancer.

Cancer Res. 2013; 73: 4791-4800https://doi.org/10.1158/0008-5472.CAN-13-0587Pfister DG Spencer S Adelstein D et al.

Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology.

J Natl Compr Canc Netw. 2020; 18: 873-898https://doi.org/10.6004/jnccn.2020.0031Nutting C.M. Morden J.P. Harrington K.J. et al.

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial.

Lancet Oncol. 2011; 12: 127-136https://doi.org/10.1016/S1470-2045(10)70290-4Langendijk J.A. Doornaert P. Verdonck-de Leeuw I.M. et al.

Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

J. Clin. Oncol. 2008; 26: 3770-3776https://doi.org/10.1200/JCO.2007.14.6647Van Der Laan B.F.A.M. Van Der Laan H.P. Bijl H.P. et al.

Acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia.

Radiother. Oncol. 2015; 115: 56-62https://doi.org/10.1016/j.radonc.2015.01.019Van De Water T.A. Lomax A.J. Bijl H.P. et al.

Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer.

Int. J. Radiat. Oncol. Biol. Phys. 2011; 79: 1216-1224https://doi.org/10.1016/j.ijrobp.2010.05.012Sio T.T. Lin H.K. Shi Q. et al.

Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes.

Int J Radiat Oncol Biol Phys. 2016; 95: 1107-1114https://doi.org/10.1016/j.ijrobp.2016.02.044Blanchard P. Garden A.S. Gunn G.B. et al.

Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis.

Radiother. Oncol. 2016; 120: 48-55https://doi.org/10.1016/j.radonc.2016.05.022Holliday E.B. Kocak-Uzel E. Feng L. et al.

Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.

Med. Dosim. 2016; 41: 189-194https://doi.org/10.1016/j.meddos.2016.01.002Van Der Laan H.P. Van De Water T.A. Van Herpt H.E. et al.

The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study.

Acta Oncol. (Madr). 2013; 52: 561-569https://doi.org/10.3109/0284186X.2012.692885Sharma S. Zhou O. Thompson R. et al.

Quality of life of postoperative photon versus proton radiation therapy for oropharynx cancer.

Int. J. Part. Ther. 2019; 5: 11-17https://doi.org/10.14338/IJPT-18-00032.1Mohan H. Tahlan A. Mundi I. et al.

Non-neoplastic salivary gland lesions: A 15-year study.

Eur. Arch. Oto-Rhino-Laryngology. 2011; 268: 1187-1190https://doi.org/10.1007/s00405-010-1460-3

Mucous glands in the developing human rhinopharynx.

Laryngoscope. 1977; 87: 987-995https://doi.org/10.1288/00005537-197706000-00016Holmberg K.V. Hoffman M.P.

Anatomy, biogenesis and regeneration of salivary glands.

Monogr. Oral Sci. 2014; : 1-13https://doi.org/10.1159/000358776

Anatomy, Head and Neck, Salivary Glands. 2021 Jun 11.

StatPearls. StatPearls Publishing, Treasure Island, FL2021Valstar M.H. de Bakker B.S. Steenbakkers R.J.H.M. et al.

The tubarial salivary glands: A potential new organ at risk for radiotherapy.

Radiother. Oncol. 2020; https://doi.org/10.1016/j.radonc.2020.09.034Bernier J. Cooper J.S. Pajak T.F. et al.

Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501).

Head Neck. 2005; 27: 843-850https://doi.org/10.1002/hed.20279Brouwer C.L. Steenbakkers R.J.H.M. Bourhis J. et al.

CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines.

Radiother. Oncol. 2015; 117: 83-90https://doi.org/10.1016/j.radonc.2015.07.041

Target delineation for postoperative treatment of head and neck cancer.

Oral Oncol. 2018; 86: 288-295https://doi.org/10.1016/j.oraloncology.2018.08.011Yom S.S. Torres-Saavedra P. Caudell J.J. et al.

NRG-HN002: A randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer.

Int. J. Radiat. Oncol. 2019; 105: 684-685https://doi.org/10.1016/j.ijrobp.2019.08.038

Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer.

Semin. Radiat. Oncol. 2009; : 43-52https://doi.org/10.1016/j.semradonc.2008.09.008Bentzen S.M. Constine L.S. Deasy J.O. et al.

Quantitative analyses of normal tissue effects in the clinic (QUANTEC): An introduction to the scientific issues.

Int. J. Radiat. Oncol. Biol. Phys. 2010; S3: 76https://doi.org/10.1016/j.ijrobp.2009.09.040Deasy J.O. Moiseenko V. Marks L. et al.

Radiotherapy dose-volume effects on salivary gland function.

Int. J. Radiat. Oncol. Biol. Phys. 2010; 76: S58https://doi.org/10.1016/j.ijrobp.2009.06.090